The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the Advisory Committee on Immunization Practices (ACIP)—whose appointment was ...
Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with ...
Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...
The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working ...
With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...
A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...
Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...
Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. After inking a deal worth up to $690 million to take on worldwide rights to the med last week, the FDA has doled out an ...
Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...
In a bid to expand its reach in the attention-deficit/hyperactivity disorder (ADHD) market, Collegium Pharmaceutical has struck a deal to ...
Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...
Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results